Shots:

• The P-III study evaluates the cardiac safety profiles & efficacy of Ontruzant vs reference trastuzumab in 367 patients with HER2 positive early or LA BC for 4yrs. after randomization
• Patients were randomized to receive 8 cycles of either Ontruzant or TRZ with concurrent neoadjuvant CT. After surgery- patients received 10 cycles of biosimilar trastuzumab or TRZ completing 1yrs. of treatment
• In follow up study- the reduction in asymptomatic LVEF at both groups- 3 patients recovering with LVEF ≥ 50%- no cases of heart failure or cardiac death observed- EFS rates (82.8% vs 79.7%)- OS rates (93.1% vs 86.7%)- number of events i.e. recurrence- progression- or death (17.2% vs 21%)

  | Ref: Globe Newswire | Image: Samsung Bioepis